CN112826849A - Compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects and preparation method thereof - Google Patents
Compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects and preparation method thereof Download PDFInfo
- Publication number
- CN112826849A CN112826849A CN202110046747.0A CN202110046747A CN112826849A CN 112826849 A CN112826849 A CN 112826849A CN 202110046747 A CN202110046747 A CN 202110046747A CN 112826849 A CN112826849 A CN 112826849A
- Authority
- CN
- China
- Prior art keywords
- rhubarb
- clove
- preparation
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 90
- 238000002360 preparation method Methods 0.000 title claims abstract description 57
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 42
- 150000001875 compounds Chemical class 0.000 title claims abstract description 27
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 24
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 22
- 239000007788 liquid Substances 0.000 claims abstract description 34
- 241000628997 Flos Species 0.000 claims abstract description 5
- 239000007787 solid Substances 0.000 claims abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 55
- 241000219061 Rheum Species 0.000 claims description 54
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 54
- 244000223014 Syzygium aromaticum Species 0.000 claims description 37
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 13
- 238000005303 weighing Methods 0.000 claims description 13
- 239000000341 volatile oil Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 239000006196 drop Substances 0.000 claims description 6
- 239000000469 ethanolic extract Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 4
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 4
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000004033 plastic Substances 0.000 claims description 4
- 229920003023 plastic Polymers 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 3
- 229940040145 liniment Drugs 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940126678 chinese medicines Drugs 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 239000012982 microporous membrane Substances 0.000 claims description 2
- 239000012452 mother liquor Substances 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 abstract description 39
- 230000000694 effects Effects 0.000 abstract description 35
- 241000894006 Bacteria Species 0.000 abstract description 26
- 229940088710 antibiotic agent Drugs 0.000 abstract description 26
- 229940079593 drug Drugs 0.000 abstract description 24
- 230000002401 inhibitory effect Effects 0.000 abstract description 15
- 208000003251 Pruritus Diseases 0.000 abstract description 13
- 238000002474 experimental method Methods 0.000 abstract description 12
- 241000700605 Viruses Species 0.000 abstract description 10
- 206010053615 Thermal burn Diseases 0.000 abstract description 7
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 7
- 206010022000 influenza Diseases 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 5
- 238000001228 spectrum Methods 0.000 abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 abstract description 4
- 230000007794 irritation Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 208000004371 toothache Diseases 0.000 abstract description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 24
- 208000015181 infectious disease Diseases 0.000 description 20
- 206010052428 Wound Diseases 0.000 description 19
- 208000027418 Wounds and injury Diseases 0.000 description 19
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 18
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 16
- 239000010282 Emodin Substances 0.000 description 16
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 16
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 16
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 16
- 241000191967 Staphylococcus aureus Species 0.000 description 16
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 16
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 16
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 16
- 235000019441 ethanol Nutrition 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 229940124350 antibacterial drug Drugs 0.000 description 14
- 229930182555 Penicillin Natural products 0.000 description 13
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 12
- 239000005770 Eugenol Substances 0.000 description 12
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 12
- 244000052616 bacterial pathogen Species 0.000 description 12
- 229960002217 eugenol Drugs 0.000 description 12
- 229920000742 Cotton Polymers 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 10
- 206010059866 Drug resistance Diseases 0.000 description 10
- 241000193998 Streptococcus pneumoniae Species 0.000 description 10
- 230000003385 bacteriostatic effect Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 229940049954 penicillin Drugs 0.000 description 10
- 241000193830 Bacillus <bacterium> Species 0.000 description 9
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 8
- 150000004056 anthraquinones Chemical class 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 7
- 230000003628 erosive effect Effects 0.000 description 7
- 230000007803 itching Effects 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 6
- 241000191963 Staphylococcus epidermidis Species 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 229960003085 meticillin Drugs 0.000 description 6
- 210000001331 nose Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 208000033809 Suppuration Diseases 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 208000008960 Diabetic foot Diseases 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000010634 clove oil Substances 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 4
- 229940056360 penicillin g Drugs 0.000 description 4
- 210000003800 pharynx Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000186427 Cutibacterium acnes Species 0.000 description 3
- 241000758993 Equisetidae Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010018612 Gonorrhoea Diseases 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000007923 nasal drop Substances 0.000 description 3
- 150000002960 penicillins Chemical class 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010002515 Animal bite Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 206010061695 Biliary tract infection Diseases 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010011409 Cross infection Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- 206010052359 Gingival abscess Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 206010048723 Multiple-drug resistance Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010029803 Nosocomial infection Diseases 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 240000004980 Rheum officinale Species 0.000 description 2
- 235000008081 Rheum officinale Nutrition 0.000 description 2
- 206010039986 Senile pruritus Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000003103 anti-anaerobic effect Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 208000003167 cholangitis Diseases 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 229960005233 cineole Drugs 0.000 description 2
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940072132 quinolone antibacterials Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 241000186146 Brevibacterium Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 206010024572 Lip ulceration Diseases 0.000 description 1
- 208000032923 Lobar pneumonia Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 206010028034 Mouth ulceration Diseases 0.000 description 1
- 241000187481 Mycobacterium phlei Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029315 Neuromuscular blockade Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 241000228150 Penicillium chrysogenum Species 0.000 description 1
- 241000228153 Penicillium citrinum Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000223253 Rhodotorula glutinis Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 208000012876 acute enteritis Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000033354 avian tuberculosis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000000312 effect on influenza Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940055036 mycobacterium phlei Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects and a preparation method thereof, relates to the technical field of natural plant traditional Chinese medicines, and aims to solve the technical problems of clinical treatment of bacterial infection and antibacterial medicines mainly relying on antibiotics and chemical synthesis. The ratio of radix et rhizoma Rhei to flos Caryophylli is 3-2: 1-2. Experiments prove that the Chinese medicinal preparation can be prepared into liquid preparations or solid preparations, can treat burns, scalds, toothache, skin itch, prevent and treat influenza and the like, is used for inhibiting bacteria and resisting viruses, has the advantages of no toxic or side effect, no irritation, easy acceptance by patients and wide antibacterial spectrum, and is suitable for popularization and application.
Description
Technical Field
The invention relates to natural plant traditional Chinese medicines, in particular to a compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects and a preparation method thereof, which are used for inhibiting bacteria and resisting viruses.
Background
Currently, clinical treatment of bacterial infections still relies on the use of antibiotics. The discovery and application of antibiotics to human beings is a great revolution of human beings. However, with the wide clinical use of antibiotics, inevitable harm also appears, so that not only the use of antibiotics is in danger, but also the health of human beings is seriously threatened again due to the appearance of 'super drug-resistant bacteria'.
Medical researchers have indicated that approximately 50% of the antibiotics are abused worldwide each year, and that this ratio is even close to 80% in china. Antibiotics are generally available without prescription in china, india and pakistan, which in part has led the general public to abuse, misuse antibiotics. Local doctors have to use more potent antibiotics to treat patients, again resulting in more drug resistance of the pathogens. Due to abuse of drugs, germs adapt to the antibiotic environment quickly, and various 'super germs' emerge successively.
Furthermore, DNA contamination due to antibiotic abuse is also another major factor contributing to "superbacteria". The rapid increase in the types and numbers of bacterial resistance genes cannot be explained by random mutation of organisms. Bacteria can not only exchange genes within the same species, but also between different species, and can even obtain genes from DNA scattered from the same species that have died. Therefore, the drug-resistant gene is rapidly transmitted among bacteria, and the generation of 'super pathogen' is further promoted.
The antibiotic can kill pathogenic bacteria and cause damage to human body. The medicine enters the stomach through the oral cavity and is absorbed into the blood through the intestinal tract and is conveyed to each cell of a human body, the medicine reaching the focus part can perform the sterilization function on pathogenic bacteria, the medicine in other tissues does not perform the sterilization function, but metabolic products are discharged out of the body through the liver and the kidney, and the medicine has certain damage effect on viscera such as the liver and the kidney, such as chloramphenicol, lincomycin, tetracycline, erythromycin and the like, and needs to be metabolized in the liver.
In addition, many antibiotics such as penicillin, streptomycin, etc. can cause allergic reactions, such as anaphylactic shock, mild rashes, fever, hematopoietic system suppression, etc., and even damage to the nervous system, such as central nervous system, hearing, vision, peripheral nervous system lesions, neuromuscular block, etc.
In summary, the invention and application of antibiotics and synthetic antibacterial drugs is one of the greatest achievements in the medical field of the 20 th century. The application of antibiotics and synthetic antibacterial drugs to human beings effectively cures various serious bacterial infectious diseases, effectively reduces the death rate of various serious bacterial infectious diseases, and further raises the climax of research and development and wide application of antibacterial drugs. In the middle of the 20 th century, over 500 kinds of antibiotic raw material medicines are on the market, and the clinical common varieties of the antibiotic raw material medicines are over hundreds. Before the enormous achievements of development and application of antibacterial drugs by human beings, the danger of infectious diseases starts to be overcome, and the application of antibiotics and synthetic antibacterial drugs also becomes desirable. However, it has been found that some bacterial infectious diseases, which are originally easy to treat, are now subject to new changes, and the antibiotics or synthetic antibacterial drugs, which are originally effective, are no longer effective in controlling the infection. The fact that pathogenic bacteria develop resistance to antibiotics is quickly documented, and the potential for fire resistance to develop and spread of some pathogenic bacteria is very alarming. According to statistics, the drug resistance rate of staphylococcus aureus to common antibiotic penicillin G is only 1% in the early 40 th century and is over 90% in the hurdle at the end of the last century; methicillin-resistant staphylococcus aureus (MRSA) with extremely high drug resistance and extremely high pathogenicity has the separation rate of 2% in 1974 and rapidly increases to 39.7% by the end of the last century, and becomes a main pathogenic bacterium causing serious bacterial infection in hospitals. At the same time, penicillin-resistant streptococcus pneumoniae (PRSP), another drug-resistant strain that causes severe community infections, has also developed rapidly. At the end of the last century, the separation rate of hospitals in major cities in China reaches 22.5 percent through sampling investigation, the separation rate of hospitals in the United states reaches 33.5 percent, and cases killed by drug-resistant bacteria infection are increased year by year. The gonorrhoeae caused by gonococcal infection is expected to be cured quickly by penicillin G treatment, but 60% of the existing gonococcal have drug resistance, and penicillin G has difficulty in controlling the development and delay. In the 80 s of the 20 th century, when quinolone antibacterial drugs are synthesized to be on the market, clinical pathogenic bacteria are very sensitive to the novel antibacterial drugs, the drug-resistant strains are almost zero, but after the quinolone antibacterial drugs are widely used for 20 years, the drug resistance rate of the clinical pathogenic bacteria to the synthetic antibacterial drugs rapidly rises. It is proved that the clinically used effective antibacterial drugs are possible to have resistant strains, and a plurality of pathogenic bacteria can also have resistance to a plurality of antibacterial drugs, namely multiple drug resistance. The development and spread of pathogenic bacterial resistance has posed a serious threat to human health. The WHO issues a warning for this: "the new superbacteria, which are resistant to all drugs, will bring the human back to the past years of infectious disease.
Still another serious problem is the very intractable multi-drug resistant infection of gram-positive cocci, which are resistant to almost all antibacterial drugs except individual antibiotics, and pose a great threat to clinical use, and have attracted global shock and attention. They include methicillin-resistant staphylococcus aureus (MRSA), methicillin-resistant staphylococcus epidermidis (MRSE) and methicillin-resistant hemolytic staphylococcus, the latter two staph being coagulase-negative, also known as methicillin-resistant coagulase-negative staphylococcus (MRCNS); penicillin-resistant streptococcus pneumoniae.
Streptococcus pneumoniae is originally highly sensitive to both penicillin and ampicillin. The streptococcus pneumoniae has drug-resistant strains to penicillins since the beginning of the 80 s, penicillin-resistant streptococcus pneumoniae is separated from various places in the future, and the drug resistance rate of the streptococcus pneumoniae to penicillins in some countries and regions is up to more than 40%. Multiple drug resistance caused by methicillin-resistant staphylococcus aureus (MRSA) has been a serious clinical problem, and the MRSA infection rate has been significantly higher than in the past, such as 2.4% MRSA incidence in 1975 and 35% rise in 1996 in the united states. In particular, the nosocomial infection MRSA accounts for a high proportion caused by Staphylococcus aureus, and the nosocomial infection MRSA accounts for 60-80% of the Japanese 1999 report. The reported MRSA incidence rate difference among various regions is large, and JAC reports that the MRSA incidence rate among different countries in Europe is less than 1% in 1999 and can reach 80% in the highest; the MRSA incidence rate reported in various places of China also fluctuates between 20% and 80%, China journal of medicine in 2001 published the results of Chinese bacterial drug resistance monitoring research, 9 regions monitored in 1998-1999 have the incidence rates of 27.55% and 15.67% for hospitalized infected patients MRSA and 81.82% for hospital-infected patients MRSA, 15.57% and 41.67% for community infection and hospital-infected patients MRSE, respectively, and the incidence rates of MRSA and MRSE in hospital-infected patients are obviously higher than the incidence rate of community infection.
Penicillin resistance of streptococcus pneumoniae to penicillin was first discovered in the mid 60 s, but it was noted that the outbreak of pneumonia caused by penicillin-resistant streptococcus pneumoniae (PRSP) was first developed in south africa in 1977. PRSP has been isolated worldwide and has become one of the most striking focuses on drug-resistant positive coccal infections. Penicillin G resistant streptococcus pneumoniae (PRSP) separation rates have increased significantly worldwide in recent years, particularly in some european countries, some regions of the united states, and some regions of south east asia where PRSP has been as high as 40% to 70%.
Disclosure of Invention
The invention aims to: in order to overcome the situation that antibiotics and chemically synthesized antibacterial drugs are still mainly relied on in clinical treatment of bacterial infection in the market at present, the invention provides a compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects and a preparation method thereof.
The invention relates to a Chinese medicinal compound prescription from plants for resisting bacteria, inflammation and virus and a preparation method of a preparation thereof. The method extracts effective components from medicinal plants by a simple, environment-friendly and convenient production method to prepare various external preparations: liquid preparation, nose drop, ointment, plastics, liniment, suppository, oral preparation, etc.
The invention provides a compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects, which adopts two traditional Chinese medicines, namely rhubarb and clove, and comprises the following raw materials in percentage by weight: rhubarb, clove and rhubarb, wherein the ratio of rhubarb to clove is 3: 1; radix et rhizoma Rhei, flos Caryophylli, and radix et rhizoma Rhei, flos Caryophylli, 2: 2
In recent years, the rheum officinale has a large number of cases reported in the anti-infection aspect: the compound preparation has obvious curative effect on acute abdominal diseases such as acute biliary tract infection, acute pancreatitis, acute appendicitis and the like. Rhubarb is also commonly used to treat common infections and inflammations, such as carbuncle and furuncle, cellulitis, purulent pharyngolaryngitis, mouth and lip ulcer, acute conjunctivitis, and gingival abscess. The two cooked rhubarb tablets prepared by different processes are used for treating and observing suppurative tonsillitis of children, and the contrast observation is carried out on 30 patients treated by other medicines, so that the two groups taking the cooked rhubarb tablets have good effects and show better antipyretic and anti-inflammatory effects; in the control group, 11 of 30 patients are treated by erythromycin and TMP, and 19 patients are treated by artificial bezoar, and the curative effect of the control group is not obviously different from that of the new and old mature rhubarb products.
The modern clinic can be used for treating epidemic meningitis, lobar pneumonia, acute biliary tract infection, acute parotitis, acute appendicitis, acute infectious icterohepatitis, acute enteritis, bacillary dysentery, digestive tract hemorrhage, pharyngolaryngitis, gingival abscess, dermatitis, eczema, gonorrhea, herpes zoster, etc.
According to the reports of the literature, rhubarb has the inhibition effect on bacteria, fungi, viruses and the like, has a wide antibacterial spectrum, and has the inhibition effect on staphylococcus, hemolytic streptococcus, diphtheria bacillus, gonococcus, mycobacterium phlei, brucellosis bacillus, plague bacillus, typhoid fever, paratyphoid bacillus, dysentery bacillus, cerumen bacillus, gonococcus and the like in different degrees. Modern pharmacological research considers that emodin, aloe-emodin and rhein have antibacterial and anti-inflammatory effects, and the lowest in vitro inhibitory concentrations of emodin (I) and aloe-emodin (II) to staphylococcus aureus, 209P escherichia coli and Shigella flexneri are respectively 15mg/L, 480mg/L, 120mg/L, 7.5mg/L, 600mg/L and 60mg/L in the bearing forest. The minimum inhibitory concentration of the clinically isolated 119 strains of staphylococcus aureus is 20-160 mg/L in I and 10-80 mg/L in II. After the induction resistance test, II generates the drug resistance, while I does not generate the drug resistance. The results of the reports of the Wangwang, Chen Smart and Minghua show that rhein, emodin and aloe-emodin which are anthraquinone derivatives have strong bacteriostatic action on 100 clinically common anaerobic bacteria, and 8 mug/ml can inhibit the growth of 76-91% of the anaerobic bacteria, wherein the rhein-anthraquinone derivatives can inhibit the growth of 90-100% of strains of the most common fragile bacillus, and compared with common anti-anaerobic bacteria medicaments, the MIC of the rhein-anthraquinone derivatives is slightly higher than that of metronidazole, but compared with other anti-anaerobic bacteria medicaments, such as cephalothin and the like, the MIC of the rhein-anthraquinone derivatives is approximately similar to or better than that of the rhein-anthraquinone derivatives. Experiments also show that the rhubarb anthraquinone derivative is mainly used for inhibiting bacteria but not killing bacteria, and the action part of the rhubarb anthraquinone derivative can interfere the formation of cell walls of anaerobic bacteria and the permeability of cell membranes.
Chen Zhi Ben and Chen Qin Hua reported that in the 30 s, Fujian folk secret recipe used rhubarb to treat venereal diseases including acute gonorrhea, early syphilis and chancroid, but had definite curative effect but had the side effect of discharging the lower-jiao. Experiments are carried out on the MIC of the gonococci by using rhein, rhein analogues (chrysophanol oxidation products), emodin, aloe-emodin and the like with stronger activity, and the results are as follows: the 4 anthraquinone derivatives have strong antibacterial effect on clinically separated gonococcus by rhein. The penicillin positive control is sensitive to three strains, but has poor effect on the other two strains, the latter two strains are possibly drug-resistant strains, and the inhibition effect of 5 clinically isolated strains is parallel to that of penicillins although the MIC of rhein is greater than that of penicillin. In order to determine whether several clinically isolated gonococcal strains are resistant to rhein, experiments are carried out by taking standard strains stored in the biological product verification of the Ministry of health as reference, and the results show that the MIC of the emodin is greater than 32, and the rhein and analogues thereof are all 8, which are much higher than the bacteriostatic value of the clinically isolated strains and are equivalent to the bacteriostatic value M IC4-8 mu g/ml of rhein extracted from leguminous plants to the gonococcal strains in 1949, and further show that the bacteriostatic action of the rhein to the gonococcal strains is positive. The anti-inflammatory effect of the keemun on the emodin is used as an experiment, and the result shows that the emodin can obviously inhibit the plantar swelling caused by the carrageenan and the increase of the permeability of the capillary vessels in the abdominal cavity caused by acetic acid, has obvious inhibiting effect on the acute pleurisy caused by the carrageenan and has anti-inflammatory effect. Thereby providing basis for the anti-inflammatory effect of the traditional Chinese medicine rhubarb. The experimental result also shows that the emodin has quick response, has better antagonistic action on early-stage exudation of inflammation, increased capillary permeability, leukocyte migration and the like, and has obvious antagonistic action on acute inflammation.
Besides the antibacterial action, rhubarb has the antiviral action: the rhubarb decoction has strong inhibition effect on influenza virus, and also has the effects of orphan virus, hepatitis B virus, poliovirus and the like. The minimum effective dose of rhubarb is 5mg per embryo by an in vitro method and an in vivo method of chicken embryos. The therapeutic index of the emodin for Wangquan et Georgi to resist HSV-2333 strain is 4.0, 2.4 and 3.9 times that of acyclovir serving as a reference product, and the therapeutic index of the emodin for Wangquan et Georgi to resist coxsackie virus B group virus is 4.7, 1.0 and 2.9 times that of ribavirin serving as a reference product. The drug effect is better than that of two positive controls. To date, a number of chemical agents have been found to have anti-herpes virus effects, but often have been too toxic or drug resistant which limits their clinical use. The reports of Wangzhiyu and Wangzusingting show that the rhubarb ethanol extract has obvious antiviral effect on cell culture, has the effective inhibition rate of 100 mu g/ml on Herpes Simplex Virus (HSV), has the prevention effect on HSV infection and has the direct killing effect on virus particles. The rhubarb ethanol extract has extremely low cytotoxicity, does not have cytotoxicity at 20000 mug/ml, even is beneficial to cell growth, and suggests that the rhubarb ethanol extract can be taken orally for treating systemic infection, such as encephalitis, visceral infection and the like, which is incomparable with any medicine for treating HSV infection.
The effective parts of clove have the inhibiting effect on bacteria, staphylococcus and tubercle bacillus. Clove oil and eugenol have strong inhibition effect on brucella and avian tuberculosis in test tubes, and have obvious inhibition effect on common disease-curing dermatophytes. Because clove oil and eugenol have no irritation to skin and are well absorbed. Octopm and the like have antibacterial and anti-inflammatory effects, and comparison of in vitro antibacterial activities of 15 crude drug alcohol extracts and effective components thereof shows that eugenol is highly sensitive to acne pathogenic bacteria, and observation under an oil microscope shows that the number of bacteria in unit area after inhibiting staphylococcus aureus, staphylococcus epidermidis and acne short-stick bacteria is obviously reduced compared with that before inhibiting, most of the bacteria are dissolved and dead, and lose normal forms, thus prompting that the pathogenicity of the bacteria is possibly correspondingly reduced. The Minimum Inhibitory Concentrations (MIC) of eugenol for inhibiting Brevibacterium acnes and Staphylococcus aureus are 17,106 μ g/ml respectively. Experiments also find that the eugenol and the erythromycin have a synergistic bacteriostatic action. The research of Xiaining and the like shows that eugenol has strong inhibiting effect on staphylococcus aureus and propionibacterium acnes (P.ace, Propionibacterium vulgaris); further experiments show that the eugenol and the cineole have the synergistic P.ane resistance function; the p.ane oil microscopic observation of the eugenol and the cineole inhibits that the number of bacteria/unit area is obviously reduced compared with that before inhibition, and most of the bacteria are dissolved and dead and lose normal forms. Staphylococcus aureus, corynebacterium acnes (p.acnes), staphylococcus epidermidis are closely related to pathogenesis of pustules and inflammatory papules of acne, and eugenol can reduce the occurrence of acne through inhibiting acne pathogenic bacteria. The study of Zhoujiangxin and the like shows that the bacteriostatic component of clove is enriched in clove oil. The eugenol not only can inhibit bacteria, but also has good inhibiting effect on the synthesis of extracellular water-soluble and water-insoluble glucan of streptococcus mutans, thereby achieving the effects of removing dental plaque, cleaning oral cavity and preventing dental caries. The study of Zhoujiangxin and the like shows that clove oil has different degrees of inhibition effects on the growth of common food molds (aspergillus flavus, aspergillus fumigatus, penicillium chrysogenum, penicillium citrinum and rhodotorula glutinis), is a good natural preservative, and has the effective component of eugenol.
Rhubarb and clove are the two most common Chinese medicines in life, although the researches on the rhubarb and the clove and the active ingredients contained in the rhubarb and the clove are many, the researches on the antibacterial action mainly report monomer compounds, and the extraction, separation and purification of the monomer compounds are difficult and time-consuming and troublesome. The two Chinese medicinal materials can be used together without extraction and separation of monomer compounds, and have antibacterial effect (antiviral effect of decoction without extraction and separation). At present, the two are not combined for research on antibiosis and antiphlogosis.
The broad-spectrum antibacterial, anti-inflammatory and antiviral compound traditional Chinese medicine has a wide antibacterial spectrum, has antibacterial effects on staphylococcus aureus, diplococcus pneumoniae, pseudomonas aeruginosa, staphylococcus epidermidis, escherichia coli and candida albicans, and also has anti-inflammatory and antiviral effects; can be used for treating traumatic infection of various skins by being applied on the skin instead of antibiotics; can be used for preventing influenza by dripping nose; the antibacterial and analgesic effects are achieved when the antibacterial and analgesic paste is applied to the gum; it can be applied to auditory canal for relieving inflammation and pain; can be applied to the urethral orifice to relieve pain and itching. Simple and convenient use, no anaphylactic reaction and no drug resistance after multiple use. Can make the wound quickly heal. Solves the problems that a pure traditional Chinese medicine preparation replaces antibiotics and chemically synthesized antibacterial drugs, removes adverse reactions and harm of the antibiotics to human bodies, simultaneously achieves the purposes of reducing the treatment cost and reducing the serious environmental pollution caused by the antibiotics and the chemically synthesized antibacterial drugs in the production process. The traditional Chinese medicine of the invention, general antibacterial agent (broad-spectrum antibacterial, anti-inflammatory and antiviral compound traditional Chinese medicine), has simple preparation and low cost, the effective period of the effective components is more than two years, and the effective period is longer than that of antibiotics.
The treatment method of the medicine of the invention comprises the following steps:
used for treating burn and scald:
the treatment method of the medicine of the invention comprises the following steps:
used for treating burn and scald: skin becomes hard to change color but not damaged; skin blisters: coating a layer of absorbent cotton on the burning and scalding part or the blister, dripping the absorbent cotton on the absorbent cotton, keeping the absorbent cotton moist for 1 to several hours until the pain disappears and the skin returns to the normal state. The water bubbles are absorbed naturally.
For toothache: placing the medicated cotton ball with the medicinal liquid on the painful teeth, and biting until the pain disappears.
For skin itch: the liquid medicine is applied to the itching part, and is almost applied to the itching part, but the root of the itching part is not removed.
Prevention and treatment of influenza: during influenza epidemic, as long as a few drops of liquid medicine are dripped in the nasal cavity and the pharynx, the liquid medicine can be put into a throat spray to be sprayed into the oral cavity or directly atomized, and can freely come in and go out in public places without infection, so that the influenza prevention device has good prevention effect; in the early stage of cold (red and swollen throat, nasal cavity pain and eye discomfort), a few drops of medicinal liquid are dripped into nasal cavity and pharyngeal portion, so that the medicinal liquid can directly act on respiratory tract where virus and bacteria propagate, and the propagation of virus and bacteria is killed or inhibited, so that the virus and bacteria cannot be attacked. Cold has already been attacked, the nose runs, and blockage: a few drops of liquid medicine are dripped into the nasal cavity, so that mucus secretion can be reduced, symptoms can be relieved, and smooth respiration can be guaranteed.
As a trauma therapy: construction engineering construction, such as railway repair, bridge building, army daily training, firefighter daily training and fire fighting actual combat, and knife wound and scald of people in daily life, when small wound is continuous, the liquid medicine is particularly suitable for treating carelessness of daily life, four limbs such as fingers, are injured, and are scratched by sharp instruments such as a kitchen knife, and the liquid medicine can be directly smeared on the wound at any time, and the wound can not be inflamed in the next day; if the wound is red, inflamed and suppurative, the pus can be squeezed out, the liquid medicine is coated on the wound for two days, the medicine is applied for several times every day, and the wound can be healed on the third day.
For the treatment of cervical erosion: the liquid medicine is directly applied to the cervical erosion part which is treated after the uterus dilatation, and the affected part can be basically cured once.
For example, the ear is accidentally injured; the liquid preparation can be dripped on a cotton swab which is used for wiping several circles in the auditory canal, so that the pain in the ear is not caused immediately. In a cat that had been treated for a dog bite, the broken left forelimb exposed the bone and the cat could not walk normally. After the liquid preparation coated with the compound is applied for three times, the wound scabs heal, and the cat walks normally.
Can be used for treating urethral orifice pain and itch: the urethral orifice is washed clean, and the liquid medicament is directly smeared on the urethral orifice, so that the pain and itch feel disappears immediately.
Can be used for treating oral cavity, tongue blister and erosion: the liquid medicine is applied or dropped on the bleb or the erosion part for several times a day until healing.
The invention relates to an extraction preparation process (method) of a compound prescription of rhubarb and clove, which comprises two processes, namely a first preparation process, and can be used for preparing liquid medicaments, such as nasal drops, solution agents and the like; the second preparation process can be used for preparing solid preparations, such as suppository, plastics, tablet, ointment, etc. The specific preparation process flow is as follows:
the preparation method comprises the following steps: firstly, extracting volatile oil and volatile components of Chinese medicinal material clove by using distillation method, adding rhubarb into residue, and using ethyl alcohol solution to extract all the components of two Chinese medicinal materials. The weight of each component is as follows: 3-12 g of rhubarb and 1-12 g of clove.
The liquid medicine prepared by the prescription is 100-200 ml.
The liquid preparation can also be added with auxiliary materials consisting of 0.02-0.04 g of broad-spectrum antibacterial preservative ethylparaben and 0.7-1.4 g of isotonic regulator sodium chloride.
The method for preparing the liquid medicament comprises the following steps:
1) weighing 10g of clove, adding 200 ml of purified water, heating, and extracting volatile oil and volatile substances.
2) Adding 30g of rhubarb and ethanol into the decoction dregs and the aqueous solution to ensure that the alcohol content in the mixture reaches 50 percent, and soaking for 24 hours;
3) filtering with six layers of gauze;
4) and (3) recovering the ethanol from the mother liquor, adding the volatile oil, the volatile substances, sodium chloride, ethylparaben and distilled water to 1000 ml, adjusting the pH value to 5.5-6.5 by using 10% NaHCO3, placing the mixture in a refrigerator for more than 48 hours, filtering the mixture by using a 1.2 mm microporous membrane, filling the mixture under the aseptic condition, and sealing the opening for later use.
The preparation method can also multiply the dosage which is put in once according to the actual production scale.
The second preparation method comprises the following steps:
weighing radix et rhizoma Rhei and flos Caryophylli (weight ratio of 3: 1), mixing, pulverizing into small granules, distilling to separate volatile components, extracting the desired parts with 70% ethanol, recovering ethanol extractive solution, making into extract, and measuring content. During production, volatile components are mixed into the extract, and then the materials are fed according to the required amount.
The method for preparing the solid medicament comprises the following steps:
1) weighing 30g of rhubarb, 10g of clove, crushing into small particles, and adding 1000 ml of water to soak for 1 hour;
2) heating and extracting for 4 hr to obtain volatile oil and volatile components.
3) And taking out the residue in the extractor and drying.
4) Weighing dry residues, performing reflux extraction for 3-5 times by using 57% -83% ethanol solution in an amount which is 4-7 times that of the dry residues, wherein each time is 1.5 hours, and filtering.
5) Mixing filtrates, recovering ethanol, and concentrating to obtain extract. Weighing and measuring the content.
The advantages are that: the quality of the Chinese medicinal preparation prepared from the extract prepared by the method can be ensured.
The preparation method can also multiply the dosage which is put in once according to the actual production scale. The traditional Chinese medicine in the prescription of the invention is only two: rhubarb and clove. The Chinese medicinal material feeding weight ratio is characterized in that: 10.2-25.8 g of rhubarb and 3.4-8.6 g of clove. Wherein, the extraction solvent in the preparation method (one) is 33 to 59 percent ethanol solution; the extraction solvent in the second preparation method is 57-83% ethanol solution.
The invention uses the extract after content measurement as the production raw material, and can clearly know how much preparation is produced and how much extract needs to be put in. The produced product reaches the standard, and the product quality is ensured. Overcomes the common diseases that the traditional Chinese medicine preparation has different raw material production areas and different active ingredient contents in medicinal materials, and the quality is not easy to ensure.
Features and effects of the invention
The invention is a pure Chinese medicinal preparation, has no toxic or side effect, has no irritation, is easy to be accepted by patients, and can replace antibiotics to treat and prevent skin trauma infection when being smeared on the skin; can be used for preventing influenza and treating rhinitis by dripping into nose. The use is simple and convenient, the anaphylactic reaction is avoided, and the wound can be quickly healed. Solves the adverse reaction and harm to human body caused by replacing antibiotics with pure traditional Chinese medicine preparation, extracts effective components from medicinal plants by a simple, environment-friendly and convenient production method, and can be prepared into various external preparations: liquid preparation, nose drop, ointment, plastics, liniment, suppository, oral preparation, etc. Meanwhile, the treatment cost is reduced, and the serious environmental pollution caused in the production process of antibiotics is reduced. In addition, the preparation is simple, the artificial cultivation technology of the main raw materials is mature, the production base is determined by the state, the problem of land desertification does not exist in a large amount of cultivation, the price is low, the purchase is easy, and the effective period of the medicine is two years longer than that of the antibiotic.
Drawings
FIG. 1 is a graph of the emodin standard curve of the present invention.
Detailed Description
The invention discloses a compound traditional Chinese medicine formula consisting of rhubarb and clove and having broad-spectrum antibacterial and antiviral effects and a preparation method of a preparation thereof, which are explained in detail by combining with an embodiment as follows:
example 1
The traditional Chinese medicine raw materials and the dosage of the traditional Chinese medicine are 3000-12000 g of rhubarb and 1000-12000 g of clove (1000 times of the dosage of the formula).
The preparation method adopting the raw materials comprises the following steps:
1) adding 12000 g of clove 1000-00 and 200000 ml of water, soaking for more than 6 hours, and extracting volatile oil and volatile components;
2) adding 3000-12000 g of rhubarb and 12000 g of ethanol into the decoction dregs and the water solution to ensure that the alcohol content reaches 50 percent, and soaking for 24 hours;
3) filtering by a plate frame; adding the volatile oil and volatile components, 2800 g of NaCl 700-; heating the filtrate to boil, refrigerating for more than 24 hours, filtering with pulp board, filtering with plate frame, bottling under aseptic condition, and packaging into 1 ten thousand 10ml vials (100000 ml).
Example 2:
the traditional Chinese medicine raw materials and the dosage of the traditional Chinese medicine raw materials in the embodiment are 3000g of rhubarb and 1000g of clove (1000 times of the dosage of the formula). The preparation method adopting the raw materials comprises the following steps:
1) weighing 3000g of rheum officinale and 1000g of clove (the weight ratio of the medicines is 3: 1) crushing into small particles, and soaking in 10000 ml (10 times) of purified water for 1 hour;
2) reflux extraction for 5 h. Obtaining volatile oil and volatile components.
3) The residue was taken out and dried.
4) Weighing dry residue, adding 5 times of 70% ethanol solution, reflux extracting for three times, each for 1.5 hr, filtering
5) Mixing filtrates, and recovering ethanol to obtain extract. Carrying out content measurement;
when the preparation is prepared, the extract with known content is added. Before feeding, the extracted volatile oil and volatile components are uniformly mixed in the extract (care is taken to prevent high temperature).
Content determination:
the content of the Chinese medicinal extract can be determined by ultraviolet spectrophotometry. Emodin is used as a standard substance, and the absorption maximum is at the position of lambda of 515 nm.
1 Standard Curve plotting
Weighing emodin 6mg precisely, placing in 50ml volumetric flask, dissolving with ether and diluting to scale, and shaking up. 0.5, 1.0, 2.0, 3.0, 4.0, 5.0ml of the diluted solution was precisely measured, and the diluted solution was placed in 25ml volumetric flasks, respectively, and diethyl ether was distilled off in a water bath, and a 5% sodium hydroxide-2% ammonium hydroxide mixed alkali solution (hereinafter referred to as mixed alkali) was added to the solution to prepare 2.4, 4.8, 9.6, 14.4, 19.2 and 24.0. mu.g/ml solutions. After 30min, absorbance was measured at a wavelength of 515nm using mixed base as a blank. Taking the absorbance as a vertical coordinate and the concentration as a horizontal coordinate, and making a regression curve, wherein the standard curve is as follows: a is 0.0423-0.009(R is 0.9999, n is 6), which shows that the emodin is good in the concentration range of 2.4-24.0 mug, and the emodin standard curve is shown in figure 1.
2 preparation of test solution
60mg of dry extract of 70% ethanol extract was precisely weighed, and 5ml of 10% sulfuric acid and 10ml of chloroform were added. Heating in water bath, refluxing and hydrolyzing for 2 h. After the chloroform solution was aspirated with a pipette, 10ml of chloroform was added thereto and refluxed for 1 hour. The chloroform solutions were combined and washed with a small amount of purified water. Chloroform was placed in a separatory funnel and extracted with mixed bases in portions. The alkali liquor is combined and washed by a small amount of chloroform. The chloroform solution was discarded and the base solution was adjusted to 25ml volumetric flask scale and heated on boiling water bath for 4min, cooled to room temperature and left to stand for 30 min. As a test solution.
3 determination of the content of the test sample
The absorbance of the test sample is measured on an ultraviolet spectrophotometer, and the content of the test sample is measured in the table.
Content of free anthraquinone
The invention discloses a Chinese medicinal composition, general antibacterial agent, comprising rhubarb horsetails and clove (the weight ratio of rhubarb horsetails to clove is 3: 1, rhubarb horsetails to clove is 2: 2), having broad-spectrum antibacterial action, wherein the antibacterial spectrum is broad, and the detailed description is provided below with reference to the examples:
example 3
Bacteriostatic spectrum of general antibacterial agent
TABLE 1 Effect of general antibacterial on Staphylococcus aureus
TABLE 2 Effect of general antibacterial agents on pneumococci
TABLE 3 Effect of general antibacterial agent on Pseudomonas aeruginosa
And (4) conclusion: the result of an external bacteriostatic experiment of the extract shows that the extract has obvious bacteriostatic action on staphylococcus aureus, pneumococcus and pseudomonas aeruginosa, and the staphylococcus aureus is strongest, which has stronger bacteriostatic action on the three bacteria than a reference medicament furametpus nasal drop.
Anti-infection experiment (test tube dilution)
Medicine general antibacterial agent
[ note ] one: bacterial inhibition without apparent turbidity
Example 4
Anthraquinone derivatives are known as the main active ingredients of rhubarb for antibacterial action, and especially rhein, emodin and aloe-emodin have the best action. The antibacterial effect of the anthraquinone derivative of rhubarb has close relationship with the chemical structure of the anthraquinone derivative of rhubarb. Modern pharmacological tests also prove that the eugenol contained in the aroma emitted by the clove is more than 5 times stronger than carbolic acid in bactericidal capacity, and has excellent air disinfection effect. It has inhibitory effect on pathogenic fungi, coccus, streptococcus, and Bacillus such as pneumonia, dysentery, pyocyania, large intestine, typhoid fever, and influenza virus.
Experimental strains
Staphylococcus aureus ATCC2611, Staphylococcus epidermidis ATCC26069, Escherichia coli ATCC24752 and Candida albicans ATCC10231 are all standard strains purchased from China pharmaceutical and biological product institute.
Batch number of rhein standard: 0756-9505 purchased from China pharmaceutical and biological products institute
In the experiment, the MIC value of the general antibacterial agent to 4 bacteria in the urogenital tract is determined by adopting a test tube double dilution method and an agar plate method, and specific results are shown in Table 1.
MIC result (mg/ml) of general antibacterial agent for in vitro antibacterial action
And (4) conclusion: the results of in vitro bacteriostasis experiments show that the extract has effects on 4 bacteria in the urogenital tract. Wherein the 70% ethanol extract has antibacterial effect (except for Staphylococcus epidermidis) higher than that of control rhein.
Example 5
The general antibacterial agent has little toxicity and is safer and more reliable than antibiotics
LD of general antibacterial agent50Measurement of (2)
In the drug acute toxicity experiment, the LD of general antibacterial agent cannot be found out by using the conventional dosage for mice50Or maximum tolerated dose. We tried to perfuse ICR mice with a pasty general antibacterial agent and the mice were half killed when the volume was as high as about 0.7ml, thus proving that the general antibacterial agent is less toxic.
Example 6
First, curative effect test
1 prevention and/or treatment of colds
In the influenza period, in order to prevent infection, the oral tablet prepared by the formula can be contained in the mouth, or nasal drops are dripped into the nose, or the liquid can be put into a throat spray and sprayed into the oral cavity or directly atomized, so that good prevention effect can be achieved.
1 medicine for preventing and/or treating cold
Note:
the effect is shown: has no common cold after administration
The method has the following advantages: the cold (after) is relieved
2 prevention and/or treatment of traumatic infections
When the skin is lacerated and punctured by a sharp tool; the skin of the cupping glass is soaked and damaged; mosquito bites, itchy skin, skin damage after scratching, and the like. In order to prevent inflammation, suppuration and itching of the damaged part of the skin, the wound can not be infected, suppurated and itchy by applying the liquid preparation of the composition on the damaged part.
If there is wound with wound inflammation and suppuration, squeezing out pus, applying the liquid preparation of the composition on suppuration part, and if the wound is not large, applying the composition for 1-2 times to heal the wound.
2 prevention and/or treatment of traumatic infections
Note:
the effect is shown: wound is not infected after the drug is applied
The method has the following advantages: the wound is not infected continuously after the drug is applied
3 promoting wound healing, for pets:
in a cat that had been treated for a dog bite, the bone had been exposed in the damaged left forelimb and the cat could not walk normally. After the liquid preparation coated with the compound is applied for three times, the wound is healed, and the cat walks normally.
4 treating cervical erosion
The liquid preparation prepared by the composition is used by a gynecologic king doctor of Ningxia Chinese medicine research institute in 2001 to clinically treat more than ten patients with cervical erosion: after expanding uterus, the affected part is cleaned, and the affected part can be cured after being generally applied with the medicine once. The patients with extra serious disease need to be applied twice.
Treating cervical erosion
The effect is shown: disappearance of ulcer surface
The method has the following advantages: reduction of ulcer surface
5 treating effect on burn and scald
When the skin on the hand is burnt or scalded, the wounded part needs to be wrapped by the absorbent cotton, and the liquid medicine of the prescription is continuously dripped on the absorbent cotton to keep the absorbent cotton at proper humidity. The skin on the hand heals and is not painful.
Treating burn and scald
The effect is shown: pain disappears and skin recovers
6 can be used for treating senile pruritus
Can be used for treating senile pruritus
The effect is shown: the itching symptom disappears immediately, and the original damaged skin heals
Note: the symptoms of itching can disappear immediately, but cannot be eradicated.
Second, introduction of three cases after using the product
Case 1: is used for treating diabetic foot, namely a 60-year-old female diabetic patient, and the wound of the diabetic foot can not heal for a long time after infection. The injured feet are swollen and shiny, and no wrinkles are seen. The liquid formulation of the present compound was applied to the skin of her diabetic foot several times (no application to a damaged wound). Half an hour later, the swollen instep begins to subside swelling, no longer shines, and several wrinkles appear, and the diabetic foot symptoms are alleviated.
Case 2: for post-cancer decubitus infection: insomnia due to wound pain. After the medicine is applied, the pain is relieved, and people can sleep at night.
Case 3: the fingers are scalded by the hot pot, and small bubbles are generated at the scalded part, which is very painful. Wrapping the medicated cotton on the bubble, and dripping medicinal liquid to keep the medicated cotton moist. The next day, the cotton wool was removed and the blisters had dried and the pain had disappeared. On the third day, the redness of the scald disappeared and the skin returned to original shape.
Claims (9)
1. A compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects is characterized in that: the adopted raw materials are two traditional Chinese medicines, namely rhubarb and clove, and the weight ratio of the rhubarb to the clove is as follows: the ratio of radix et rhizoma Rhei to flos Caryophylli is 3-2: 1-2.
2. The compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects as claimed in claim 1: the preferable weight ratio of the rhubarb to the clove is as follows: rhubarb, clove and rhubarb, wherein the ratio of rhubarb to clove is 3: 1; rhubarb, clove and rhubarb are mixed at a ratio of 2: 2.
3. The preparation method of the compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects as claimed in claim 1 comprises the following steps: the weight of each component is as follows: 3-12 g of rhubarb and 1-12 g of clove, and the mixture is prepared into liquid medicine.
The method for preparing a liquid medicament comprises the steps of:
1) weighing 10g of clove, adding 200 ml of purified water, heating, and extracting volatile oil and volatile substances.
2) Adding 30g of rhubarb and ethanol into the decoction dregs and the aqueous solution to ensure that the alcohol content in the mixture reaches 50 percent, and soaking for 24 hours;
3) filtering with six layers of gauze;
4) and (3) recovering the ethanol from the mother liquor, adding the volatile oil, the volatile substances, sodium chloride, ethylparaben and distilled water to 1000 ml, adjusting the pH value to 5.5-6.5 by using 10% NaHCO3, placing the mixture in a refrigerator for more than 48 hours, filtering the mixture by using a 1.2 mm microporous membrane, filling the mixture under the aseptic condition, and sealing the opening for later use.
4. The preparation method of a compound Chinese medicine with broad spectrum antibacterial, anti-inflammatory and antiviral effects as claimed in claim 3, wherein the volatile oil and volatile components of the Chinese medicine clove are extracted by distillation before the step 1), the residue is added with rhubarb, all the components of the two Chinese medicines are extracted by ethanol solution, and the ethanol solution with 33% -59% is used as extraction solvent.
5. The preparation method of the compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects as claimed in claim 3 comprises the following steps: the liquid medicament is 100-200 ml, and auxiliary materials consisting of 0.02-0.04 g of broad-spectrum antibacterial preservative ethylparaben and 0.7-1.4 g of osmotic adjusting agent sodium chloride are also added into the liquid medicament.
6. The preparation method of the compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects as claimed in claim 1 comprises the following steps: a method for preparing a solid pharmaceutical dosage form comprising the steps of:
1) weighing 30g of rhubarb, 10g of clove, crushing into small particles, and adding 1000 ml of water to soak for 1 hour;
2) heating and extracting for 4 hr to obtain volatile oil and volatile components.
3) And taking out the residue in the extractor and drying.
4) Weighing dry residues, performing reflux extraction for 3-5 times by using 57% -83% ethanol solution in an amount which is 4-7 times that of the dry residues, wherein each time is 1.5 hours, and filtering.
5) Mixing filtrates, recovering ethanol, and concentrating to obtain extract. Weighing and measuring the content.
7. The preparation method of the compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects as claimed in claim 6 comprises the following steps: weighing rhubarb and clove before the step 1), wherein the weight ratio of the mixture is 3: 1, crushing the raw materials into small particles, separating volatile components by a distillation method, extracting required parts by using 70% ethanol, recovering ethanol extract, preparing extract, performing content measurement, mixing the volatile components into the extract during production, and feeding according to required amount, wherein 57-83% of ethanol solution is an extraction solvent.
8. The preparation method of the compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects as claimed in claim 7 comprises the following steps: the weight ratio of the traditional Chinese medicinal materials fed into the rhubarb and the clove is as follows: 10.2-25.8 g of rhubarb and 3.4-8.6 g of clove.
9. The compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects as claimed in claim 1: the Chinese medicine can be made into liquid preparation, nose drop, ointment, plastics, liniment, suppository, and oral preparation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110046747.0A CN112826849A (en) | 2021-01-15 | 2021-01-15 | Compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110046747.0A CN112826849A (en) | 2021-01-15 | 2021-01-15 | Compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112826849A true CN112826849A (en) | 2021-05-25 |
Family
ID=75928041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110046747.0A Pending CN112826849A (en) | 2021-01-15 | 2021-01-15 | Compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112826849A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114949063A (en) * | 2022-07-14 | 2022-08-30 | 重庆医药高等专科学校 | Preparation method and application of effective part of Dachengqi decoction with synergistic antibacterial effect |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1096689A (en) * | 1993-06-24 | 1994-12-28 | 宁夏卫生学校 | Anti-cold and detoxicating nose drops |
-
2021
- 2021-01-15 CN CN202110046747.0A patent/CN112826849A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1096689A (en) * | 1993-06-24 | 1994-12-28 | 宁夏卫生学校 | Anti-cold and detoxicating nose drops |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114949063A (en) * | 2022-07-14 | 2022-08-30 | 重庆医药高等专科学校 | Preparation method and application of effective part of Dachengqi decoction with synergistic antibacterial effect |
CN114949063B (en) * | 2022-07-14 | 2023-05-16 | 重庆医药高等专科学校 | Preparation method and application of effective part with synergistic antibacterial effect |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106334067B (en) | Gynecological gel containing silver ion antibacterial agent, preparation method and application | |
RU2655616C1 (en) | Application of phillyrin/phillygenin composition when preparing a medicament or medical product for the relief and/or treatment of viral diseases and medicament or medical product for treatment of viral diseases | |
US9662360B2 (en) | Treatment of herpes, pseudomonas, staph, and hepatitis | |
HU229230B1 (en) | Medical composition for the treatment of herpes simplex virus and other infectious diseases | |
CN103385926B (en) | Antibiosis gel for curing cervical and vaginal diseases of gynaecology | |
CN113332244B (en) | Antiviral oral spray and preparation method thereof | |
CN113081928A (en) | Plant bacteriostatic gel and preparation method and application thereof | |
US10478463B2 (en) | External-use medicament for cleaning and care of the ovaries, vagina, and vulva | |
CN110721095B (en) | Herbal oral bacteriostatic spray containing propolis and preparation method thereof | |
CN100353953C (en) | Traditional Chinese medicina preparation for treating oral cavity, throat disease and its preparation method | |
CN107007778A (en) | Treat traditional Chinese medicine gel of gynaecological imflammation and preparation method thereof | |
CN104922248A (en) | Antibacterial and anti-inflammatory Chinese herbal compound gel and preparation method thereof | |
CN110384725A (en) | A kind of preparation of Chinese traditional medicine composition and its activity extract for adjusting oral cavity flora | |
CN112826849A (en) | Compound traditional Chinese medicine with broad-spectrum antibacterial, anti-inflammatory and antiviral effects and preparation method thereof | |
CN105193705A (en) | Gel containing triclosan | |
CN106309746A (en) | Traditional Chinese medicine composition, preparation method thereof and oral health product | |
CN104094979B (en) | Application of the Folium Salicis Babylonicae in disinfectant is prepared | |
CN106237029B (en) | A kind of aloe antibiotic gel and preparation method thereof | |
CN103920010B (en) | There is pharmaceutical composition of hemostasis and pain-relieving and antiinflammatory action and its production and use | |
CN107149611B (en) | Mongolian medicine rhinitis spray and preparation method thereof | |
CN111345288A (en) | A colloidal carrier capable of forming antibacterial and antiviral coating on the surface of respiratory protector, colloidal tincture and application thereof | |
CN109820901A (en) | A kind of Traditional Chinese medicinal gel preparation with sterilization | |
CN113633717B (en) | Electronic atomized liquid composition for nasal cavity care, application thereof and obtained care product | |
CN101766731A (en) | Tea polyphenol acne resistant external preparation | |
CN104906379A (en) | Traditional Chinese medicine ointment for treating bullous impetigo and preparation method of ointment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210525 |
|
RJ01 | Rejection of invention patent application after publication |